MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Parabilis Medicines

News headline image
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines Appoints Biopharmaceutical Finance Leader Alan M. Sebulsky to Board of Directors
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines Expands Executive Leadership Team
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and Helicon Platform
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines Highlights Promising Preliminary Clinical Results in Patients with Adamantinomatous Craniopharyngioma from Ongoing FOG-001 Clinical Trial at SNO 2025
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines Receives FDA Fast Track Designation for FOG-001, the First and Only Direct Inhibitor of the β-catenin:TCF Interaction, for the Treatment of Desmoid Tumors
From Parabilis Medicines
Via Business Wire
News headline image
CORRECTING and REPLACING Parabilis Medicines Presents Clinical and Preclinical Data Demonstrating Broad Potential of Helicon™ Peptides at AACR-NCI-EORTC 2025
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines Presents Clinical Data Demonstrating First-Ever Drugging of Key Cancer Driver with FOG-001
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines Appoints Fawzi Benzaghou, M.D., as Chief Medical Officer
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines to Present Overview of Ongoing Phase 1/2 Study of FOG-001, a β-cateninTCF4 Inhibitor, at Upcoming Medical Meetings
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines Reports Positive Proof-of-Mechanism Data for Groundbreaking ERG Degrader Program
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines to Present First Preclinical Data on ERG Degrader Program at AACR Annual Meeting
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines to Present Trial-in-Progress Poster on Phase 1/2 Study of FOG-001, a β-cateninTCF4 Inhibitor, at ASCO Gastrointestinal Cancers Symposium
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines Presents Updates on Clinical Progress of β-cateninTCF4 Inhibitor, Helicon™ Portfolio and Discovery Engine at J.P. Morgan Healthcare Conference
From Parabilis Medicines
Via Business Wire
News headline image
Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform
From Parabilis Medicines
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story